mAbxience | Our story: moving forward
Our story:
moving forward
-
2019
• New partnerships in EU, Russia, Japan and other key markets
• Australian GMP certification granted to mAbxience León
• New state-of-the-art mAbxience facility opening in Bs As -
2018
• Alliances with leading pharma companies in EE, USA, and Australia
• Turkish GMP certification grantes to mAbxience León
• First rituximab launch in the Jordan market
• Business Development of the Year Award 2018 by GGBA -
2017
• European GMP certification granted to mAbxience León
• Initiation of project for the construction of a new mAb facility in Bs As
• Scientific Advices with the EMA and the FDA
• Clinical trials of rituximab and bevacizumab completed
• Expasion of global acces of rituximab -
2016
• Bevax® (bevacizumab) launch in Argentina
• Project with WHO and UCAB to develop Palivizumab biosimilar
• Biosimilar Initiative of the Year Award 2016 by GGBA -
2015
• mAbxience León plant: inauguration
-
2014
• Genhelix biopharmaceutical plant acquisition (León, Spain)
• Novex® (rituximab) launch in Argentina -
2013
• Clinical trial recruitment (bevacizumab)
-
2012
• mAbxience Buenos Aires plant: inauguration
• ANMAT GMP certification to mAbxience Bs As
• First industrial batch
• First clinical trial recruitment (rituximab) -
2010
• Acquisition and start of construction of pharmADN (mAbxience Bs As facility)
-
2009
• Established in Europe
• Start of R&D activities
ANMAT: National Administration of Drugs, Foods and Medical Devices.
WHO: World Health Organization.
UCAB: Utrecht Centre for Affordable Biotherapeutics.
GMP: Good Manufacturing Practices.
AEMPS: Spanish Agency for Medicines and Medical Devices
EMA: European Medicines Agency
FDA: US Food Drug Administration
TGA: Australia Therapeutic Goods Administration
GGBA: Global Generics & Biosimilar Awards